PCLX-001

PCLX-001

• CAS Number: 1215011-08-7
• UNSPSC Description: PCLX-001 is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC50s of 5 nM (NMT1) and 8 nM (NMT2), respectively. PCLX-001 can induce cell apoptosis, has anti-cancer activity, inhibits early B cell receptor (BCR) signaling, and can be used to study malignant lymphoma[1][2].
• Target Antigen: N-myristoyltransferase
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/pclx-001.html
• Solubility: DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O=S(NC1=C(C)N(C)N=C1CC(C)C)(C2=C(Cl)C=C(C3=CC(N4CCNCC4)=NC=C3)C=C2Cl)=O
• Molecular Weight: 537.51
• References & Citations: [1]Michael Weickert, et al. Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies. Blood. 2019. 134(s1):3362.|[2]Beauchamp E, et al. Targeting N-myristoylation for therapy of B-cell lymphomas. Nat Commun. 2020 Oct 22;11(1):5348.
• Shipping Conditions: Room Temperature
• Clinical Information: Phase 1